α-lipoic acid and combination PPAR α/γ-agonism

Journal of Applied Research

Volumn 5, Issue 4, 2005, Pages 508-509

  Toth, Peter P ^a,b,c  

^a Sterling Rock Falls Clinic Ltd ^*  (United States)

^b CGH Medical Center   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TESAGLITAZAR; THIOCTIC ACID; TRIACYLGLYCEROL;

ATHEROSCLEROTIC PLAQUE; CATABOLISM; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG MECHANISM; EDITORIAL; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; INSULIN SENSITIVITY; LIGAND BINDING; LIPID METABOLISM; LIPOPROTEIN SYNTHESIS; NONHUMAN; OXIDATIVE STRESS; RECEPTOR BINDING;

EID: 33750820860     PISSN: 1537064X     EISSN: 1537064X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (4)

1. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
2. Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL-C. Circulation. 1997;96:2137-2143.
3. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289.
4. Nissen SA, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294:2581-2586.